Growth hormone is a large molecule that has a long list of jobs. It affects bone development, protein formation, sugar utilization, and fat metabolism. That’s the breadth that is a problem for researchers attempting to isolate any one of those functions, however – pull one lever and some of the others pull.
A team of researchers in Australia decided to explore a possible question: did the fat-metabolism activity in growth hormone have to be disconnected from all the other growth hormone activities? This led to the generation of a short peptide which represented the tail end sequence of growth hormone and has now become one of the more commonly requested peptides from growth hormone in metabolic laboratories.
This overview includes what the compound really is, how it differs from the parent hormone, what the published literature indicates, and, more important what the published literature does not indicate. The research on peptides and fat loss is more complex than what is often reported in the media.
What Is HGH Fragment 176-191?
The human growth hormone (hGH) is a polypeptide of approximately 22 kDa with 191 amino acids. HGH Fragment 176-191 is a synthetic sequence of the last sixteen residues (C-Terminal region) of the same chain with a molecular weight in the range 1.8kDa.
There’s a size difference which does matter. The fragment is a small part of the parent molecule and doesn’t contain the parts of the molecule that bind to growth hormone receptors in the traditional way.
The area has been of interest since the early work in the 1970s and 1980s indicating the presence of lipolytic activity in the C-terminus (not across) hGH. Researchers at Monash University led by Frank Ng followed up on that observation and created an analog, AOD-9604, which is a hexadecapeptide from residues 177-191, with an added N-terminal tyrosine for stability. It is important to remember when reading literature that most of the information that is labeled as “HGH Fragment” was actually done with AOD-9604.
The peptide is now commercially available, produced by solid-phase synthesis, as a lyophilized powder for laboratory use.
It’s not growth hormone. It is a “piece of the puzzle” that is studied as a model compound.
How Does HGH Fragment 176-191 Differ from Full Growth Hormone?
| HGH Fragment 176-191 | Human Growth Hormone | |
|---|---|---|
| Molecular size | ~16 amino acids, ~1.8 kDa | 191 amino acids, ~22 kDa |
| Research focus | Adipose tissue and lipid metabolism | Growth, development, and systemic metabolism |
| Biological targets | Predominantly adipocytes; β3-adrenergic signaling implicated in rodent models | Growth hormone receptors across liver, muscle, bone, and adipose tissue |
| IGF-1 relationship | No meaningful IGF-1 elevation reported in published studies | Stimulates hepatic IGF-1 production |
| Investigated pathways | Lipolysis, cAMP signaling, hormone-sensitive lipase activity | JAK2/STAT5 signaling, IGF-1 axis, glucose and protein metabolism |
| Current research scope | Narrow and metabolic; no approved indication | Approved clinical use in defined endocrine conditions |
How Researchers Study HGH Fragment 176-191
Laboratory experiments on this peptide have focused on a relatively limited number of questions.
Using isolated adipocytes, the effect of the fragment on the biochemical machinery of fat breakdown, such as cyclic AMP accumulation, phosphorylation of hormone-sensitive lipase and release of glycerol (a marker of triglyceride hydrolysis) is studied.
Changes between body weight, fat pad mass and lean tissue have been monitored in rodents, including genetically obese models, during treatment.
From a scientific perspective, the receptor pathway has attracted particular interest. In 2001, Heffernan and colleagues reported in Endocrinology that both human growth hormone (hGH) and AOD-9604 restored suppressed β3-adrenergic receptor (β3-AR) mRNA expression in obese mice to levels comparable with lean controls. They also found that the metabolic effects, including body weight reduction and increased lipolysis, were absent or markedly diminished in β3-AR knockout mice. These findings suggested that the β3-adrenergic pathway plays a critical role in mediating the metabolic actions observed in rodent models.
Comparative studies have been used to test the effect of the fragment on metabolism in the presence of full-length hGH, and whether there are separable metabolic responses from growth and IGF-1 responses.
Potential Research Areas
Fat Metabolism Research
The main question is: can a short peptide affect lipid handling without an activation of the entire growth hormone signalling cascade? Some activity supported by preclinical data, open magnitude and durability.
Lipolysis Studies
The peptide can be used as a convenient probe to study the lipolytic signaling pathway and release of glycerol and free fatty acids are clean, measurable endpoints in adipocyte culture.
Obesity Research Models
In genetically obese rodent strains, there will be a response to the fragment. While these models have proved to be very useful mechanistically, they are not necessarily representative of real-world outcomes, and this is clearly reflected in the case of this compound.
Metabolic Regulation
The researchers have studied the peptide’s effect on glucose control or insulin sensitivity. To date, the adverse glucose effects of full hGH have not been reported.
Body Composition Research
Reduction in adipose mass in rodents, without significant changes in lean tissue, has suggested possible tissue selectivity that has yet to be fully understood.
Energy Balance
The exact mechanism behind the changes has not been determined, whether it is the result of higher fat oxidation, or changes in energy expenditure or something else.
Hormonal Signaling
The most lasting research benefit is the fragment which can be used to probe the downstream effect of which fragments of the growth hormone molecule are responsible.
Current Scientific Research
| Research area | Model | Reported observation | Principal limitation |
|---|---|---|---|
| Lipolytic signaling | Isolated adipocytes | Increased cAMP and hormone-sensitive lipase activity | In vitro conditions poorly reflect intact physiology |
| β3-AR dependence | β3-AR knockout mice (Heffernan et al., 2001) | Metabolic effects are absent without β3-AR | Rodent-specific receptor biology |
| Body composition | Obese rodent strains | Reduced fat mass; lean mass largely preserved | Genetic obesity models translate poorly |
| IGF-1 response | Rodent and human studies | No significant IGF-1 elevation reported | Absence of effect is not evidence of benefit |
| Clinical efficacy | Human obesity trials (AOD-9604) | A 12-week study showed modest separation from placebo; a 24-week Phase 2b trial in 536 participants did not meet its primary endpoint | Development discontinued in 2007; full results never peer-reviewed |
| Safety and tolerability | Six controlled trials | 900+ participants | Well tolerated, no serious adverse events attributed to the peptide | Safety data do not establish efficacy |
On the positive side, the pre-clinical results have been fairly consistent, and, on the negative side, the human evidence hasn’t backed them up. This aspect of this compound’s record is the most scientifically important.
Potential Advantages Being Investigated
Clinical safety data are available for AOD-9604 under specific oral and intravenous study conditions. These findings cannot be extrapolated to other sequences, formulations, routes or unregulated products.
These observations are not intended as effects.
Limitations of Current Research
- All human efficacy data are negative with the primary endpoint that really mattered, and Phase 2b results were never published in a peer-reviewed journal.
- Mechanistic evidence is highly dependent on rat and mouse models that have known limitations for translation.
- The β3-AR pathway is distinctively different from rodent to humans.
- Much of the clinical literature does not refer to the unmodified 176-191 sequence, but rather to AOD-9604.
- Since its development was halted, no large and controlled trials have been performed.
- The compound is prohibited by the World Anti-Doping Agency (WADA), limiting its use in certain research settings.
Research Handling and Storage
Peptide integrity is achieved by discipline. The following are examples of general laboratory procedures which apply to lyophilized research peptides:
- Storage form – supplied lyophilized, which is much more stable than material in solution.
- Temperature – refrigerated or frozen storage (according to supplier’s Certificate of Analysis); repeated freeze-thaw will damage peptide chain.
- Light protection – protect from light by placing in amber vials or covered containers.
- Sterile technique – work in sterile environment with sterile consumables to prevent microbial contamination.
- Moisture Control – allow vials to come to ambient temperature before opening to avoid condensation.
- Documentation – record lot numbers and receipt dates and compare to batch testing records.
Each supplier and formulation may have different storage recommendations; refer to the documentation that accompanies your batch.
Frequently asked questions
It is a man-made peptide fragment of the last 16 amino acids of human growth hormone. It is synthesized in solid phase and available as a lyophilized powder for research purposes and has been reported to have effects on lipid metabolism and on adipose tissue signaling.
No. Growth hormone is a protein of about 22 kDa and 191 amino-acids that has multiple physiological functions. The fragment is merely the C-terminal part and it does not contain the structural regions of the classical growth hormone receptor activation. They are one molecule and the other molecule has a different research profile.
Scientists examine if growth hormone has an independent lipolytic action from its growth-promoting and IGF-1 actions. Its fragment is a mechanistic tool to explore which parts of the parent hormone are responsible for which metabolic effect.
It belongs to the growth hormone sequence and is therefore often classified as a growth hormone peptide. However, in practice, it does not work as the secretagogues, like sermorelin or tesamorelin, which work on the endogenous growth hormone axis, but not directly on adipose tissue.
Size, target and scope. The fragment is approximately 1/12 of the size of the parent hormone and has been investigated mainly in relation to adipocytes, and has not been reported to increase the levels of IGF-1. Growth hormone works on a systemic level via receptors in the liver, muscle, bone and fat.
It does so because it allows to test adipose tissue signaling in a setting where there are fewer confounding endocrine influences. It has a relatively good safety profile and a well-described structure that would make it useful for mechanistic studies, even if its effectiveness in obesity has not been proven.
Peptides generally are stored on dry ice or in a freezer or refrigerator in the dark, away from moisture, and with a minimum number of freeze-thaw cycles. Sterile laboratory technique to be used for handling. Each compound and formulation has specific conditions, please consult the Certificate of Analysis supplied with each batch.
The sources of research grade materials should be those companies that provide third party purity analysis and batch-specific Certificates of Analysis. It is critical that identity, purity and lot traceability is documented for reproducible work. Current specifications and test results are displayed on our HGH Fragment product page.
Conclusion
HGH Fragment 176-191 is an interesting peptide in the world of peptides. The premise (a hormone can have discrete functions) was correct and the preclinical studies were valid. The clinical programme that ensued failed to materialise, and this is a part of the compound's scientific history, not an afterthought.
The fragment continues to be a useful and well-documented tool for laboratories engaged in studying adipocyte biology, β-adrenergic signaling or the structure-function relationships on growth hormone. Future studies might help resolve why the rodent results have not been seen in humans, which has implications beyond this study molecule.
HGH Fragment 176-191 is intended for laboratory research only. It is not meant for human or animal use, nor recommended for diagnosis, treatment, cure or prevention of any disease.
